Physician profile

Derek P Bitner

Ophthalmology · West Des Moines, IA

NPI 1134414709

$2,548.33

in general payments reported to CMS, 2019-2025

3 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$145.01

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
US Retina LLC $2,403.32 2019-2022
Horizon Therapeutics Plc $124.98 2023 Tepezza
Rxsight INC $20.03 2024 Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal)

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$78,308.51 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Derek P Bitner

$2,548.33

in general payments reported 2019-2025

Years
2019-2024
Top company
US Retina LLC

https://glasscript.com/doctor/142803/derek-p-bitner

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.